| Literature DB >> 35646724 |
Juan C Sánchez-Arcila1, Kirk D C Jensen1,2.
Abstract
Forward genetic approaches have been widely used in parasitology and have proven their power to reveal the complexities of host-parasite interactions in an unbiased fashion. Many aspects of the parasite's biology, including the identification of virulence factors, replication determinants, antibiotic resistance genes, and other factors required for parasitic life, have been discovered using such strategies. Forward genetic approaches have also been employed to understand host resistance mechanisms to parasitic infection. Here, we will introduce and review all forward genetic approaches that have been used to identify host factors involved with Apicomplexa infections, which include classical genetic screens and QTL mapping, GWAS, ENU mutagenesis, overexpression, RNAi and CRISPR-Cas9 library screens. Collectively, these screens have improved our understanding of host resistance mechanisms, immune regulation, vaccine and drug designs for Apicomplexa parasites. We will also discuss how recent advances in molecular genetics give present opportunities to further explore host-parasite relationships.Entities:
Keywords: CRISPR-Cas9; ENU; QTL; RNAi; apicomplexa; classical genetics; forward genetic screens; host immunity
Mesh:
Year: 2022 PMID: 35646724 PMCID: PMC9133346 DOI: 10.3389/fcimb.2022.878475
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Figure 1Host forward genetic screens in Apicomplexa. Common traits measured in forward genetic screens (FGS) are survival to Apicomplexa infection, symptoms related to the disease such as fever or tissue pathology, prevalence of the disease within a population, parasite load reduction, variables such as red blood cell (RBC) morphology and physiology, and immune parameters such as cytokines and parasite-specific antibody titers. (A) Classical genetic approaches use crosses between different genetic backgrounds that differ in susceptibility to infection. Rodents, pigs, and chickens have been analyzed for quantitative trait loci (QTLs) following Apicomplexa infection. In addition, more complex crosses of mice including backcrosses of murine recombinant inbred lines (RILs), or more advanced populations of RILs have been used to generate QTLs with narrow regions of association. The final objective is to map genomic regions and identify variants associated with the trait. Data is frequently represented as a QTL map showing peaks over the genetic regions with highest trait association. Candidate genes are usually indicated within the QTL. (B) Genome-wide association studies (GWAS) and genome-wide linkage analysis (GWLA) seek genotype-phenotype correlations for a variety of traits associated with disease caused by Apicomplexa; humans and chickens have been subjected to these approaches. These screens rely on a high quantity of genetic markers, or SNPs that are determined by differential oligo binding or whole genome sequencing of individuals enrolled in the study. Associations are visually displayed using Manhattan Plots, showing strength of the probability (-Log10(P)) and the chromosomal localization of the SNPs. (C) ENU mutagenesis screens are designed to generate 1 mutation in every 700 loci and relies upon small failures of the host’s DNA repair machinery. Mutagenesis screens start with a male treated with ENU and crossed with healthy females. Various breeding schemes can be used to segregate the gene causative of the induced trait (e.g. protection against Plasmodium infection). (D) CRISPR, RNAi, and gene overexpression (OE) library screens are adapted for high-throughput in vitro conditions, and can screen hundreds or thousands of genes during the process. CRISPR and RNAi inhibit while OE enhances gene function through overexpression. GFP+ parasites are often used to measure parasite proliferation to help identify host genes capable of inhibiting or promoting parasite replication and growth. Credits: Figure created in Biorender.
Host genes revealed by forward genetic screens analyzing Apicomplexa infections.
| Year | Parasite | Host | FGS | Traits | Confirmed Genes | References |
|---|---|---|---|---|---|---|
| 1989 |
| AxB/BxA RIL, H-2a congenic (mice) | Classical genetics | Resistance to chronic infection, brain cyst numbers | MHCI | ( |
| 2003 |
| (B10.Q/J × BALB/c) × B10.Q/J F1 backcross (mice) | Classical genetics | Susceptibility to infection, loss of IL-12 signaling |
| ( |
| 2006 |
| LEWxBN, LWxF344 (rats) | Classical genetics | Resistance to infection, macrophage death in response to |
| ( |
| 2021 |
| AxB/BxA RIL (mice) | Classical genetics | Resistance to secondary infection |
| ( |
| 2001 |
| AcB55 × DBA/2 F2 | Classical genetics | Resistance to blood stage infection |
| ( |
| 2007 |
| AcB55 × A/J F2 (mice) | Classical genetics | Resistance to blood stage infection |
| ( |
| 2015 |
| BMDMs from AxB/BxA RIL (mice) | eQTL | Macrophage response to infection and stimulation |
| ( |
| 2012 |
| Humans | GWAS, eQTL | Protection against severe falciparum malaria |
| ( |
| 2012 |
| C57BL/6J × C57BL/10J (mice) | ENU | Protection against ECM |
| ( |
| 2014 |
| C57BL/6J × C57BL/10J (mice) | ENU | Protection against ECM |
| ( |
| 2015 |
| C57BL/6J × C57BL/10J (mice) | ENU | Protection against ECM |
| ( |
| 2019 |
| mixed BALB/c and C57BL/6 background (mice) | ENU | Protection against ECM |
| ( |
| 2020 |
| C57BL/6 (mice) | ENU | Protection against ECM |
| ( |
| 2015 |
| SJL/J (mice) | ENU | Low mean corpuscular volume of RBC |
| ( |
| 2016 |
| SJL/J (mice) | ENU | Macrocytic anemia |
| ( |
| 2009 |
|
| ENU | RBC associated variables: maturation, size, fragility, numbers |
| ( |
| 2017 |
| SJL/J (mice) | ENU | Low mean corpuscular volume and hemoglobin concentration of RBC |
| ( |
| 2020 |
| SJL/J (mice) | ENU | Low mean corpuscular volume of RBC |
| ( |
| 2013 |
| HeLa cells (human) | RNAi | Parasite invasion |
| ( |
| 2013 |
| HeLa cells (human) | RNAi | Parasite growth |
| ( |
| 2015 |
| HeLa cells (human) | RNAi | Parasite growth in low O2 conditions |
| ( |
| 2008 |
| Huh7 hepatoma cell line (human) | RNAi | Sporozoite infection |
| ( |
| 2008 |
| Huh7 hepatoma cell line (human) | RNAi | Sporozoite infection |
| ( |
| 2015 |
| Hematopoietic progenitor cells, | RNAi | Parasite invasion |
| ( |
| 2019 |
| HepG2, Huh7 cell lines (human) | RNAi | Parasite growth |
| ( |
| 2019 |
| U20S cells (human) | Over-expression | Overriding |
| ( |
| 2021 |
| A549 lung carcinoma cell line (human) | Over-expression | Parasite growth |
| ( |
| Pre-print |
| HepG2-CD81 hepatocellular carcinoma cell line (human) | CRISPR/Cas9 | Regulators of microtube remodeling around the sporozoite vacuole |
| ( |
| Pre-print |
|
| CRISPR/Cas9 | Host cell survival to parasite infection | Type III interferon pathway and IFN-λ required for mouse resistance to infection | ( |